CLREX - Columbia Balanced Inst2 - Review the CLREX stock price, growth, performance, sustainability and more to help you make the best investments.

CNDAX - Columbia Bond A - Review the CNDAX stock price, growth, performance, sustainability and more to help you make the best investments.

Columbia reported on Tuesday an investment return of 4.7 percent on its endowment for fiscal year 2023—the highest reported return among peers who have released returns so far. This brings the ...

Summary. Columbia Strategic Income Fund Institutional Class shares returned 0.82% for Q2 2024, outperforming the Bloomberg U.S. Aggregate Bond Index's 0.07% return.

Click to enlarge Fund performance. Columbia Bond Fund Institutional Class shares returned 3.02% for the period ended March 31, 2025. The Bloomberg U.S. Aggregate Bond Index returned 2.78% for the ...

Perseverance Metals Inc. ("Perseverance" or the "Company") is pleased to announce that it has closed a non-brokered private ...

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high ...

Leading global investment firm KKR (NYSE:KKR), alongside British Columbia Investment Management Corporation (BCI), and Pinnacle Towers—an Asia-based digital infrastructure platform operating in ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) announced a strategic investment of $250 million from fund ...

MUSC Health has announced a $30 million investment to expand its emergency department services at its downtown Columbia Medical Center. The expansion will nearly double the number of beds in the ...

British Columbia Investment Management Corp. deployed a record amount of cash in private credit last year after banks pulled back from lending. The investment manager had C$8.4 billion ...

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three ...